TP53 and glioblastoma: Our data demonstrate that Olaparib overcomes apoptotic resistance and sensitizes GBM cells for death receptor-mediated apoptosis induced by TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) through up-regulation of TRAIL receptor 2 (DR5) independent of their TP53 status.